Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
2.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Sherwood V, Thomson J, Hogan S, Spender LC, South AP, Stratton M, Chelala C, Harwood CA, Proby CM, Leigh IM.

Nat Commun. 2018 Sep 10;9(1):3667. doi: 10.1038/s41467-018-06027-1.

3.

Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

Rose AM, Spender LC, Stephen C, Mitchell A, Rickaby W, Bray S, Evans AT, Dayal J, Purdie KJ, Harwood CA, Proby CM, Leigh IM, Coates PJ, Inman GJ.

Oncotarget. 2018 Feb 22;9(18):14552-14566. doi: 10.18632/oncotarget.24545. eCollection 2018 Mar 6.

4.

Targeting BRAF-mutant tumours with TGFBR1 inhibitors.

Spender LC, Inman GJ.

Aging (Albany NY). 2017 Jan 31;9(1):5-6. doi: 10.18632/aging.101169. No abstract available.

5.

Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.

Spender LC, Inman GJ.

Br J Dermatol. 2016 Dec;175(6):1140-1141. doi: 10.1111/bjd.15136. No abstract available.

PMID:
27996149
6.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

7.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

8.

Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Spender LC, Inman GJ.

Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745. Review.

9.

Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.

Spender LC, Carter MJ, O'Brien DI, Clark LJ, Yu J, Michalak EM, Happo L, Cragg MS, Inman GJ.

J Biol Chem. 2013 Feb 15;288(7):5198-209. doi: 10.1074/jbc.M112.410274. Epub 2012 Dec 14.

10.

Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Spender LC, Inman GJ.

Mol Cancer Res. 2012 Mar;10(3):347-59. doi: 10.1158/1541-7786.MCR-11-0394. Epub 2012 Jan 12.

11.

Inhibition of germinal centre apoptotic programmes by epstein-barr virus.

Spender LC, Inman GJ.

Adv Hematol. 2011;2011:829525. doi: 10.1155/2011/829525. Epub 2011 Oct 23.

12.

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

J Clin Invest. 2010 Aug;120(8):2842-57. doi: 10.1172/JCI36125. Epub 2010 Jul 1.

13.

Targeting the BCL-2 family in malignancies of germinal centre origin.

Spender LC, Inman GJ.

Expert Opin Ther Targets. 2009 Dec;13(12):1459-72. doi: 10.1517/14728220903379565. Review.

PMID:
19922301
14.

Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.

Brady G, Whiteman HJ, Spender LC, Farrell PJ.

J Virol. 2009 Jul;83(13):6909-16. doi: 10.1128/JVI.00216-09. Epub 2009 Apr 29.

15.

TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL.

Spender LC, O'Brien DI, Simpson D, Dutt D, Gregory CD, Allday MJ, Clark LJ, Inman GJ.

Cell Death Differ. 2009 Apr;16(4):593-602. doi: 10.1038/cdd.2008.183. Epub 2009 Jan 9.

16.

TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation.

Fleming YM, Ferguson GJ, Spender LC, Larsson J, Karlsson S, Ozanne BW, Grosse R, Inman GJ.

Oncogene. 2009 Feb 19;28(7):983-93. doi: 10.1038/onc.2008.449. Epub 2008 Dec 15.

PMID:
19079344
17.

TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1.

Spender LC, Inman GJ.

J Biol Chem. 2009 Jan 16;284(3):1435-42. doi: 10.1074/jbc.M808080200. Epub 2008 Nov 19.

18.

Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells.

Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, Asano T, Dittrich-Breiholz O, Kracht M, Vanhaesebroeck B, Farrell PJ.

J Gen Virol. 2006 Oct;87(Pt 10):2859-67.

PMID:
16963743
19.

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, O'Nions J, Allday M, Hoffmann I, Crawford D, Griffin B, Farrell PJ, Crook T.

Blood. 2006 Jan 1;107(1):250-6. Epub 2005 Sep 13.

20.

Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells.

Spender LC, Whiteman HJ, Karstegl CE, Farrell PJ.

Oncogene. 2005 Mar 10;24(11):1873-81.

PMID:
15688019
21.

Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV.

de Jesus O, Smith PR, Spender LC, Elgueta Karstegl C, Niller HH, Huang D, Farrell PJ.

J Gen Virol. 2003 Jun;84(Pt 6):1443-50.

PMID:
12771413
23.

Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection.

Spender LC, Cornish GH, Rowland B, Kempkes B, Farrell PJ.

J Virol. 2001 Apr;75(8):3537-46.

24.

Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ.

J Virol. 1999 Jun;73(6):4678-88.

25.

Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.

Spender LC, Hussell T, Openshaw PJ.

J Gen Virol. 1998 Jul;79 ( Pt 7):1751-8.

PMID:
9680139
26.

Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus.

Hussell T, Spender LC, Georgiou A, O'Garra A, Openshaw PJ.

J Gen Virol. 1996 Oct;77 ( Pt 10):2447-55.

PMID:
8887477
27.

Activity of penciclovir in antiviral assays against herpes simplex virus.

Bacon TH, Howard BA, Spender LC, Boyd MR.

J Antimicrob Chemother. 1996 Feb;37(2):303-13.

PMID:
8707740

Supplemental Content

Loading ...
Support Center